Stockscreener 앱 받기
568.20
2.23%
12.37
시장 영업 전:
566.05
-2.15
-0.38%
전일 마감가:
$555.83
열려 있는:
$555.81
하루 거래량:
867.88K
Relative Volume:
0.87
시가총액:
$59.19B
수익:
$14.21B
순이익/손실:
$4.46B
주가수익비율:
14.32
EPS:
39.68
순현금흐름:
$3.56B
1주 성능:
+0.17%
1개월 성능:
+4.08%
6개월 성능:
-20.88%
1년 성능:
-50.22%
1일 변동 폭
$555.81
$570.76
1주일 범위
$552.81
$577.75
52주 변동 폭
$476.49
$1,170.58
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
568.20 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.37 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
468.58 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
763.52 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
335.67 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Sepio Capital LP Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Scientech Research LLC Has $1.21 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Tamar Securities LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Woodline Partners LP - MarketBeat
Banque Transatlantique SA Reduces Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Teza Capital Management LLC Has $251,000 Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Holdings Increased by UniSuper Management Pty Ltd - MarketBeat
Focus Partners Advisor Solutions LLC Invests $538,000 in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
DnB Asset Management AS Purchases 14,323 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Nissay Asset Management Corp Japan ADV - MarketBeat
MAI Capital Management Has $566,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
United Services Automobile Association Buys Shares of 2,477 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sandoz, Regeneron Settle Eye Drug Patent Claims - Law360
Regeneron’s fast-acting IgG promises alternative to frequent allergy shots - biocentury.com
Gotham Asset Management LLC Purchases 20,624 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
REGENERON ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy - AOL.com
Alliancebernstein L.P. Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
AQR Capital Management LLC Purchases 28,865 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Can You Keep The Cat and The Relationship? Regeneron Thinks So - insights.citeline.com
A Look at Regeneron (REGN) Valuation After Positive Phase 3 Results in Myasthenia Gravis Trial - simplywall.st
Regeneron Deal Lets Sandoz Launch Eylea Biosimilar in Late 2026 - Bloomberg Law News
Regeneron’s cat and birch allergy mAbs score in Phase III trials - Yahoo Finance
Sandoz and Regeneron reach agreement over biosimilar dispute - Ophthalmology Times
Regeneron settles patent dispute with Sandoz over Eylea biosimilar - Seeking Alpha
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’ - BioSpace
Libtayo plus chemotherapy results at five years reinforce significant and durable improvements in survival - MarketScreener
Sandoz Eyes 2026 Aflibercept Launch With Regeneron Eylea Settlement - insights.citeline.com
Sandoz and Regeneron settle aflibercept dispute, paving way for US debut - The Pharma Letter
Five-Year Data from Regeneron's EMPOWER-Lung 3 Trial Shows Libtayo Plus Chemotherapy Significantly Improves Overall Survival in Advanced NSCLC Patients - Quiver Quantitative
19.4% vs 8.8%: Regeneron's Libtayo Doubles Long-term Survival in Advanced Lung Cancer Trial at 5 Years - Stock Titan
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar - Sandoz
Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials - Stocktwits
Flputnam Investment Management Co. Sells 5,992 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Raymond James Financial - MarketBeat
Royal Bank of Canada Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What's Happening With Regeneron Pharmaceuticals Stock On Monday? - Benzinga
Regeneron's allergen-blocking antibodies score phase 3 wins against cat, pollen allergies - Fierce Biotech
Samlyn Capital LLC Makes New $29.12 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-08-2025 07 - MarketScreener
Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints - MarketScreener
Regeneron advances allergy pipeline with positive Phase 3 trial results By Investing.com - Investing.com Canada
Regeneron advances allergy pipeline with positive Phase 3 trial results - Investing.com
Regeneron Pharmaceuticals, Inc. Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-In-Class Antibody-Blockers of Cat and Birch Allergies - MarketScreener
Regeneron advances allergy pipeline with two positive Phase 3 trials evaluating antibody-blockers - MarketScreener
Regeneron antibody treatments show promise against cat and birch allergies - Investing.com
Trading Recap: Is Regeneron Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Update & Entry Point Confirmation Signals - beatles.ru
Amundi Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Reports Positive Phase 3 Trial Results for Allergen-Blocking Antibodies Targeting Cat and Birch Allergies - Quiver Quantitative
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.16%
0.08%
자본화:
|
볼륨(24시간):